Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025. The Company also reminds those who have previously voted ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Australia is facing some of the biggest challenges in our history: climate change, food security, energy transition, and the ...

The quadrivalent recombinant influenza vaccine is as safe and immunogenic in children and adolescents aged 9-17 years as it ...

The Pharma world is seeing a big opportunity in GLP-1s – the new innovative fast emerging drugs for diabetes & obesity. Kiran ...

Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer Date: Thursday, June 5 th, 2025 Following the event, a replay will be hosted on Kalaris Therapeutics’ Investor ...

Nervous necrosis virus typically enters host cells via endocytosis, but it can also enter via a process called macropinocytosis.

The large molecule injectable drugs market is anticipated to expand at a CAGR of ~9% during the forecast period. Key drivers ...